049960 — Cell Biotech Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩83bn
- KR₩14bn
- KR₩54bn
- 95
- 76
- 70
- 96
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 45,960 | 45,582 | 46,873 | 50,526 | 53,787 |
Cost of Revenue | |||||
Gross Profit | 35,209 | 34,725 | 35,683 | 37,951 | 38,975 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 40,165 | 41,915 | 39,617 | 44,458 | 51,674 |
Operating Profit | 5,795 | 3,668 | 7,257 | 6,068 | 2,113 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 8,483 | 2,402 | 12,090 | 10,172 | 6,880 |
Provision for Income Taxes | |||||
Net Income After Taxes | 7,406 | 3,189 | 10,383 | 8,281 | 6,304 |
Net Income Before Extraordinary Items | |||||
Net Income | 7,406 | 3,189 | 10,383 | 8,281 | 6,304 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 7,406 | 3,189 | 10,383 | 8,281 | 6,304 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 997 | 449 | 1,465 | 1,199 | 932 |
Dividends per Share |